Synergistic anticancer activity of arsenic trioxide with erlotinib is based on inhibition of EGFR-mediated DNA double-strand break repair

Kushtrim Kryeziu, Ute Jungwirth, Mir Alireza Hoda, Franziska Ferk, Siegfried Knasmüller, Claudia Karnthaler-Benbakka, Christian R Kowol, Walter Berger, Petra Heffeter

Research output: Contribution to journalArticle

35 Citations (Scopus)

Fingerprint Dive into the research topics of 'Synergistic anticancer activity of arsenic trioxide with erlotinib is based on inhibition of EGFR-mediated DNA double-strand break repair'. Together they form a unique fingerprint.

Medicine & Life Sciences